ReviewFrontiers in veterinary science2021
Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.
Review in Frontiers in veterinary science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 121 citations in OpenAlex.
- Article
- Probiotics as Potential Enhancers of Veterinary Vaccines.Probiotics and antimicrobial proteins · 2026Review
- GnRH-Based Immunocastration Vaccines: Comparative Analysis and Role in Boar Taint Reduction.Vaccines · 2026Review
- From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic Readiness.Vaccines · 2026Article
- Association of Haematological Parameters With TLR Genes in Healthy and Distemper-Infected Dogs Haematology and TLRs in Distemper.Veterinary medicine and science · 2026Article
- Effect of PEI25k/DOTAP/cholesterol liposomal formulation on the immunogenicity of SARS-CoV-2 spike protein-encoding DNA vaccine.Biotechnologia · 2026Article
- Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.Biomaterials research · 2026Review
- Low-cost, handheld, multi-pulse electroporators for simplified nucleic acid delivery in skin.Bioengineering & translational medicine · 2026Article
- Bivalent SARS-CoV-2 spike immunization with non-replicative antibiotic resistance-free DNA vaccine induces immunity to multiple virus variants.Scientific reports · 2025Article
- Preventive Immunology for Livestock and Zoonotic Infectious Diseases in the One Health Era: From Mechanistic Insights to Innovative Interventions.Veterinary sciences · 2025Review
- Artificial Intelligence Driven Framework for the Design and Development of Next-Generation Avian Viral Vaccines.Microorganisms · 2025Review
- Aerosolized mRNA monoclonal antibodies: A new frontier in passive immunization for neonatal foals.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Hydrogels in Veterinary Vaccine Development: Types, Mechanisms, and Applications.Gels (Basel, Switzerland) · 2025Review
- Porcine Reproductive and Respiratory Syndrome Virus: Challenges and Advances in Vaccine Development.Vaccines · 2025Review
- InactivatedFrontiers in immunology · 2025Article
- Yeast vaccine production platform for human and animal infectious diseases.Frontiers in immunology · 2025Review
- Alternatives to antibiotics for sustainable livestock production in the context of the One Health approach: tackling a common foe.Frontiers in veterinary science · 2025Review
- Why the Jenner/Pasteur paradigm is insufficient for controlling vector-borne diseases and the role of microbiota-mediated interactions.Current research in parasitology & vector-borne diseases · 2025Review
- Research publications and global manufacture of veterinary vaccines against avian influenza A (2019-2023).Frontiers in veterinary science · 2025Article
- Immunotherapy in mastitis: state of knowledge, research gaps and way forward.The veterinary quarterly · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The success of inactivated and live-attenuated vaccines has enhanced livestock productivity, promoted food security, and attenuated the morbidity and mortality of several human, animal, and zoonotic diseases. However, these traditional vaccine technologies are not without fault. The efficacy of inactivated vaccines can be suboptimal with particular pathogens and safety concerns arise with live-attenuated vaccines. Additionally, the rate of emerging infectious diseases continues to increase and with that the need to quickly deploy new vaccines. Unfortunately, first generation vaccines are not conducive to such urgencies. Within the last three decades, veterinary medicine has spearheaded the advancement in novel vaccine development to circumvent several of the flaws associated with classical vaccines. These third generation vaccines, including DNA, RNA and recombinant viral-vector vaccines, induce both humoral and cellular immune response, are economically manufactured, safe to use, and can be utilized to differentiate infected from vaccinated animals. The present article offers a review of commercially available novel vaccine technologies currently utilized in companion animal, food animal, and wildlife disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.